Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.

Abstract Prolyl hydroxylases catalyze the post-translational formation of 3- and 4-hydroxyprolines in polypeptides. To date, two prolyl 4-hydroxylase families are known to exist: collagen prolyl 4-hydroxylases (C-P4Hs) which reside in the endoplasmic reticulum, and hypoxia-inducible factor prolyl 4-hydroxylases (HIF-P4Hs) which reside in either the cytoplasm or nucleus. C-P4Hs and HIF-P4Hs belong to the 2-oxoglutarate dioxygenase family and require Fe2+, 2-oxoglutarate, O2 and ascorbate in their reaction. C-P4Hs are critical enzymes in collagen biosynthesis since the formation of 4-hydroxyproline residues stabilizes the collagen triple helix at body temperature. HIF-P4Hs regulate, through hypoxia-inducible factor HIF, the expression of genes that are essential for the survival of cells during hypoxia. This thesis reports the cloning and characterization of two novel P4Hs, from human and a plant, which show some distinct features when compared to previously characterized P4Hs. The human P4H was found to have a unique transmembrane domain, with its catalytic region residing inside the lumen of the endoplasmic reticulum, its subcellular localization thus being identical to that of the C-P4Hs. However, unlike C-P4Hs, it hydroxylated HIF-α both in vitro and in cellulo. Furthermore, its expression level was induced in hypoxic conditions in most of the cell lines studied. The Arabidopsis thaliana P4H had distinct differences in its substrate specificity when compared to another previously characterized A. thaliana P4H. Interestingly, the putative peptide binding regions of the two new P4Hs characterized in this study shared some homology. Three prolyl 3-hydroxylase (P3H) isoenzymes are known to exist in vertebrates and they also belong to the 2-oxoglutarate dioxygenases. It is known that 3-hydroxyprolines are found only in collagens, being most abundant in type IV collagen. The function of this modification is as yet poorly understood, but its absence in collagen I has recently been shown to lead to recessive lethal osteogenesis imperfecta. The human P3H isoenzymes were cloned during these thesis studies, and were expressed as recombinant proteins. The kinetic properties of one of them, P3H2, which was found to be expressed in structures rich with basement membranes, was studied in detail. / Tiivistelmä Prolyylihydroksylaasit ovat entsyymejä, jotka katalysoivat 3- ja 4-hydroksiproliinien muodostumisen valkuaisaineissa. Nykyisin tunnetaan ainakin kaksi prolyyli-4-hydroksylaasien (P4H) entsyymiperhettä: endoplasmakalvostossa sijaitsevat kollageeni prolyyli-4-hydroksylaasit (kollageeni-P4H:t) sekä vähähappisissa olosuhteissa aktivoituvaa transkriptiotekijää, hypoksiaindusoituvaa faktoria (HIF), hydroksyloivat prolyyli-4-hydroksylaasit (HIF-P4H:t). HIF-P4H:t sijaitsevat sytoplasmassa ja tumassa. Sekä kollageeni-P4H:t että HIF-P4H:t kuuluvat 2-oksoglutaraattidioksygenaasien laajaan entsyymiperheeseen. Nämä entsyymit tarvitsevat kosubstraateikseen rautaa, 2-oksoglutaraattia, happea sekä C-vitamiinia. Kollageeni-P4H:t hydroksyloivat kollageenien proliinitähteitä ja ovat avainasemassa kollageenisynteesissä, sillä muodostuneet 4-hydroksiproliinitähteet ovat ehdoton vaatimus stabiilille kollageenirakenteelle. HIF-P4H:t säätelevät puolestaan niiden geenien ilmenemistä, jotka ovat välttämättömiä elimistön selviytymiselle vähähappisissa olosuhteissa. HIF-P4H:t hydroksyloivat HIF-transkriptiotekijän α-alayksikön tiettyjä proliinitähteitä hapen läsnä ollessa, joka ohjaa α-alayksikön proteasomaaliseen hajotukseen eikä aktiivista HIF transkriptiotekijää siten muodostu. Alentuneessa happipitoisuudessa HIF-P4H entsyymien toiminta estyy, HIF stabiloituu ja aktivoi kohdegeeniensä toiminnan. Kollageeni-P4H entsyymejä pidetään erityisen sopivina lääkekehityksen kohteina fibroottisten ja HIF-P4H entsyymejä iskeemisten sairauksien hoitoon. Tässä väitöskirjatyössä on karakterisoitu aiemmin tuntematon ihmisen transmembraaninen P4H entsyymi (P4H-TM). Entsyymi osoittautui indusoituvan vähähappisissa olosuhteissa useissa solulinjoissa ja hydroksyloivan HIF-transkriptiotekijää muistuttaen siten HIF-P4H entsyymejä. Kuitenkin P4H-TM:n solulokalisaatio poikkesi HIF-P4H entsyymeistä, sillä sen havaittiin sijaitsevan endoplasmakalvostossa, katalyyttinen keskus kalvoston sisällä. Näiden tutkimustulosten valossa on oletettavaa, että tällä ihmisentsyymillä on HIF:n lisäksi toinen toistaiseksi tuntematon fysiologinen substraatti. Väitöskirjassa karakterisoitiin toinen lituruohon, Arabidopsis thalianan, P4H (At-P4H-2), joka poikkesi katalyyttisiltä ominaisuuksiltaan aiemmin karakterisoidusta lituruohon P4H:sta. Näiden kahden kasvientsyymin substraattivaatimusten poiketessa selvästi toisistaan, on niillä solussa todennäköisesti spesifiset tehtävät. At-P4H-2:n oletetulla substraatin sitomisalueella on jakso, joka on 37-prosenttisesti identtinen ihmisen P4H-TM:n kanssa, minkä vuoksi At-P4H-2:n karakterisoinnin uskottiin olevan tärkeä apuväline ihmisen P4H-TM:n tutkimuksissa. Selkärankaisilla prolyyli-3-hydroksylaaseja (P3H) tiedetään olevan kolme, ja myös ne kuuluvat 2-oksoglutaraattidioksygenaaseihin. 3-Hydroksiproliinia esiintyy ainoastaan kollageeneissa, erityisesti tyypin IV kollageenissa, joka on tyvikalvojen tärkeä rakennekomponentti. 3-Hydroksiproliinin merkitystä ei tunneta vielä tarkoin, mutta tyypin I kollageenissa 3-hydroksiproliinin puutoksen on osoitettu johtavan vaikeaan luustosairauteen, osteogenesis imperfectaan. Väitöskirjatyössä ihmisen P3H:t kloonattiin ja tuotettiin rekombinanttiproteiineina. Yhden isoentsyymin (P3H2) katalyyttiset ominaisuudet määritettiin ja sen osoitettiin ilmenevän erityisesti kudoksissa, joissa on paljon tyvikalvorakenteita.

Abstract Oxygen homeostasis is critical to all animals, as both excess (hyperoxia) and reduced (hypoxia) levels of oxygen can result in pathological changes and ultimately in the loss of cellular and organismal viability. Complex systems have evolved to sense and adapt to changes in cellular oxygen availability, and the hypoxia-inducible factor HIF plays a pivotal role in this elaborate molecular network. In normoxic conditions the α-subunit of HIF becomes hydroxylated by HIF prolyl 4-hydroxylases (HIF-P4Hs 1-3), earmarking HIF-α for proteasomal degradation. Additionally, in the presence of oxygen the hydroxylation of an asparagine residue by the HIF asparaginyl hydroxylase FIH inhibits the transactivation of HIF-target genes by blocking the interaction of HIF-α with a transcriptional coactivator. In addition to being a feature of an organism’s normal life, hypoxia is also characteristic of many common diseases such as severe anemia and myocardial infarction, and it notably decreases these hydroxylation reactions, as HIF-P4Hs and FIH have an absolute requirement for oxygen as a cosubstrate. HIF-α thus escapes degradation and translocates into the nucleus, where it dimerizes with HIF-β and recruits transcriptional coactivators to the hypoxia-response elements of target genes, inducing their transcription and triggering the hypoxia response aimed at restoring cellular oxygen homeostasis. In this study we generated a genetically modified HIF-P4H-2 hypomorphic mouse line that expresses only 8% of the wild-type HIF-P4H-2 mRNA in the heart. We showed that chronic cardiac HIF-P4H-2 deficiency leads to stabilization of HIF-1α and HIF-2α and protects the heart against acute ischemia-reperfusion injury without causing any adverse effects. Furthermore, we identified and cloned a novel human transmembrane prolyl 4-hydroxylase P4H-TM and showed that it regulates HIF-1α protein levels in cellulo and hydroxylates HIF-1α in vitro similarly to the HIF-P4Hs, but may also have other physiological substrates. Using forward genetic tools we showed that lack of P4H-TM during development leads to basement membrane defects and compromised kidney function in zebrafish embryos. Finally, we demonstrated that FIH displays substrate selectivity in terms of hydroxylation and binding of HIF-1α and novel substrates Notch1-3. We showed that FIH has higher affinity for oxygen with Notch1 than with HIF-1α as a substrate, implying that FIH-mediated hydroxylation of Notch can continue in oxygen concentrations where HIF-1α hydroxylation would be markedly reduced. / Tiivistelmä Happitasapainon ylläpito on edellytys elimistön normaalille toiminnalle, koska sekä liian korkea (hyperoksia) että liian matala (hypoksia) happipitoisuus ovat elimistölle stressitiloja ja johtavat pitkittyessään haitallisiin seurauksiin. Happipitoisuuden muutosten havaitsemiseksi ja niihin reagoimiseksi onkin elimistössä kehittynyt monimutkainen säätelyjärjestelmä, jossa avainasemassa on hypoksia-indusoituva tekijä HIF. Solun happipitoisuuden ollessa normaali yksi kolmesta HIF prolyyli 4-hydroksylaasi-isoentsyymistä (HIF-P4Ht 1-3) katalysoi kahden proliinitähteen hydroksylaation HIF-α-alayksikössä. 4-hydroksiproliini toimii signaalina HIF-α:n nopealle proteasomaaliselle hajotukselle. Lisäksi HIF asparaginyyli hydroksylaasi FIH:n katalysoima HIF-α:n asparagiinitähteen hydroksylaatio estää transaktivaatiovaikutuksen. Koska HIF-P4Ht ja FIH tarvitsevat kosubstraatikseen happea, nämä hydroksylaatioreaktiot vähenevät happipitoisuuden laskiessa, jolloin HIF-α stabiloituu ja siirtyy solun tumaan, jossa se muodostaa kompleksin HIF-β-alayksikön kanssa ja houkuttelee paikalle tarvittavat kofaktorit. HIF-kompleksi tehostaa hypoksiavasteessa tarvittavien geenien luentaa sitoutumalla tumassa niiden promoottoreihin ja pyrkii näin palauttamaan solun happipitoisuuden normaaliksi. Tässä työssä luotiin geneettisesti muunneltu HIF-P4H-2 hypomorfi-hiirilinja, jonka sydämissä tuottuu vain 8 % normaalista HIF-P4H-2 lähetti-RNA:n määrästä. HIF-P4H-2:n puutoksen havaittiin johtavan HIF-1α:n ja HIF-2α:n stabiloitumiseen sydämessä ja suojaavan sydäntä kudosvaurioilta iskemian ja reperfuusion aikana aiheuttamatta haitallisia vaikutuksia. Tässä väitöskirjassa karakterisoitiin aiemmin tuntematon ihmisen transmembraaninen prolyyli 4-hydroksylaasi, P4H-TM. Sen osoitettiin säätelevän HIF-1α:n määrää soluissa ja katalysoivan HIF-1α:n kahden proliinitähteen hydroksylaatiota in vitro-olosuhteissa HIF-P4H-entsyymien tavoin. Seeprakalamallin avulla näytettiin, että P4H-TM:n puutos kalan kehityksen aikana aiheuttaa tyvikalvopoikkeavuuksia ja johtaa vakavaan munuaisen toiminnan häiriintymiseen seeprakalan poikasissa. FIH:n katalysoiman hydroksylaatioreaktion kineettisiä ominaisuuksia verrattiin tässä tutkimuksessa ensimmäistä kertaa aiemmin tunnetun HIF-α substraatin ja uusien Notch substraattien kesken. Tulokset osoittivat, että substraatin sitomisessa ja hydroksylaatiossa on merkittäviä eroja eri substraattien välillä.

Dysfunction of the central noradrenergic and dopaminergic systems is the primary neurobiological characteristic of Parkinson’s disease (PD). Importantly, neuronal loss in the locus coeruleus (LC) that occurs in early stages of PD may accelerate progressive loss of dopaminergic neurons. Therefore, restoring the activity and function of the deficient noradrenergic system may be an important therapeutic strategy for early PD. In the present study, the lentiviral constructions of transcription factors Phox2a/2b, Hand2 and Gata3, either alone or in combination, were microinjected into the LC region of the PD model VMAT2 Lo mice at 12 and 18 month age. Biochemical analysis showed that microinjection of lentiviral expression cassettes into the LC significantly increased mRNA levels of Phox2a, and Phox2b, which were accompanied by parallel increases of mRNA and proteins of dopamine β-hydroxylase (DBH) and tyrosine hydroxylase (TH) in the LC. Furthermore, there was considerable enhancement of DBH protein levels in the frontal cortex and hippocampus, as well as enhanced TH protein levels in the striatum and substantia nigra. Moreover, these manipulations profoundly increased norepinephrine and dopamine concentrations in the striatum, which was followed by a remarkable improvement of the spatial memory and locomotor behavior. These results reveal that over-expression of these transcription factors in the LC improves noradrenergic and dopaminergic activities and functions in this rodent model of PD. It provides the necessary groundwork for the development of gene therapies of PD, and expands our understanding of the link between the LC-norepinephrine and dopamine systems during the progression of PD.

<p>The brain serotonergic and dopaminergic systems broadly influence our internal experience and the ways in which we interact with the outside environment, with crucial regulatory roles in mood, sleep, appetite and the control of voluntary movement. Serotonin and dopamine neurons are themselves influenced by a wide variety of internal and external factors, many of which remain poorly understood. The central aim of this thesis was to better characterize several of these modulatory influences via exploratory investigations involving pharmaceutical agents or environmental modification. Specifically, I examined the modulatory effects of selective serotonin reuptake inhibitors (SSRIs), atypical neuroleptics and environmental enrichment with exercise on the regulation of brain serotonin and dopamine neurons.</p> <p>This thesis documents, for the first time, that (1) inhibition of the serotonin transporter (SERT) by SSRIs induces a rapid and region-selective reduction of tryptophan hydroxylase (TPH)-immunoreactive neurons in serotonergic brainstem nuclei that persists over a prolonged treatment course; that (2) selective blockade of SERT by SSRIs can rapidly induce a reduction of tyrosine hydroxylase (TH)-positive dopaminergic neurons in the substantia nigra (SN) and the ventral tegmental area (VTA) that, again, persists over a lengthy treatment course; that (3) environmental enrichment with exercise can potentiate the effect of SERT inhibition on SN dopaminergic neurons, but not the dorsal raphe nucleus (DRN) serotonergic neurons; that (4) that SSRI fluoxetine triggers a significant upregulation of microglia in the SN; that (5) environmental enrichment with exercise can reduce TPH immunoreactivity in the DRN and TH immunoreactivity in the SN and VTA, even in the absence of any pharmacological intervention, and finally, that (6) the atypical neuroleptic risperidone significantly reduces TPH in the DRN of both young and aged animals and reduces DRN Nissl counts in aged animals. Taken together, the body of work included in this thesis suggests that SSRIs, atypical neuroleptics and environmental enrichment with exercise can have profound effects on brain serotonergic and dopaminergic neurons, possibly accounting for some of the side effects and therapeutic benefits associated with these interventions.</p> / Doctor of Philosophy (PhD)

Serotonin (5-Hydroxytryptamin, 5-HT) ist ein wichtiger Neurotransmitter im Zentralnervensystem (ZNS). Seine Biosynthese erfolgt unter Beteiligung des Enzyms Tryptophanhydroxylase 2 (TPH2). Polymorphismen im TPH2 Gen beim Menschen sind Risikofaktoren bei der Entstehung von Depressionen und Angstverhalten. Die gängigsten Antidepressiva und Anxiolytika wirken auf das Serotonin System. Unklar ist, ob das komplette oder teilweise Fehlen von Serotonin im Gehirn zu Entwicklungsstörungen und neurochemischen oder psychologischen Veränderungen führt. In dieser Arbeit werden Mauslinien mit unterschiedlichen TPH2 Aktivitäten im ZNS verglichen und der Einfluss verringerter 5-HT Konzentrationen auf Entwicklung und Verhalten der Tiere untersucht. Zentrales Serotonin ist nur für die postnatale Entwicklung notwendig. Das verzögerte Wachstum von Tph2-/- Tieren ist nicht auf eine Störung der Hypothalamus-Hypophysen-Nebennieren-Achse oder auf metabolische Veränderungen zurückzuführen, sondern kann aus verringerter Vokalisation im Ultraschallbereich resultieren. Tph2-/- Mäuse wurden mit generierten Mausmodellen mit niedriger TPH2 Aktivität vergleichen. Die Ergebnisse zeigen, dass 20% weniger zentrales Serotonin nicht ausreichen, um Depression oder Angst-Verhalten herbeizuführen. Möglicherweise greifen kompensatorische Mechanismen wie ein verringerter Serotoninmetabolismus oder eine gesteigerte 5-HT1A-Rezeptorsensitivität. Der komplette Verlust von Serotonin im Gehirn führt zu einem starken depressiven und weniger ängstlich Verhalten, mit erhöhter Aggression - ohne Veränderung in Aktivität, Geruchsinn, Gedächnis und adulter Neurogenese. Fluoxetine Behandlung von Tph2-defizienten Mäusen zeigte einen Serotonin-unabhängigen Effekt dieses Antodepressivums auf Angst-Verhalten und Depression. Fluoxeine reduzieren den Serotoningehalt im Gehirn von Mäusen mit geringen TPH2-Aktivität, was zeigt, dass TPH-Aktivität die Effizienz von Serotonin beeinflussenAntidepressiva bestimmen, / Serotonin (5-HT) is a major neurotransmitter in the brain biosynthesis of which is initiated by tryptophan hydroxylase 2 (TPH2). Polymorphisms in the TPH2 gene are suggested as risk factors associated with depression and anxiety in humans. Furthermore, the most frequently prescribed antidepressants and anxiolytics target the serotonergic system. However, the question whether a complete ablation or partial reduction in brain serotonin leads to the developmental, neurochemical, or psychological abnormalities remains unresolved. In this study, I took advantage of mouse lines with various degree of decrease in TPH2 activity in order to dissect the impact of 5-HT loss on development, brain neurochemistry and behavior. Using Tph2-deficient mice I showed that central serotonin is essential for normal postnatal, but not prenatal development. Growth retardation of Tph2-/- mice was not a result of a disruption of the hypothalamo-pituitary-adrenal axis, metabolic abnormalities, or impaired thermoregulation, but could result from reduced ultrasonic vocalization. I tested Tph2-/- mice along with other newly generated mouse models with partial TPH2 reduction, and showed that 20% reduction in central serotonin is not enough to cause changes in anxiety- and depression-like behaviors most likely due to compensatory mechanisms including reduced serotonin metabolism and increased 5-HT1A receptor sensitivity. However, complete loss of central serotonin leads to a depression-like phenotype, reduced anxiety-like behavior, and exaggerated aggression, but no differences in activity, olfaction, memory, and adult neurogenesis. Fluoxetine treatment of Tph2-/- mice revealed serotonin-independent action of this antidepressant on anxiety- and depression-like behavior. Furthermore, fluoxetine drastically reduced the brain 5-HT content in mice with low TPH2 activity indicating that TPH2 activity may determine the efficiency of antidepressants targeting the serotonergic system.

La méthylation de l’ADN est une modification majeure du génome des eucaryotes permettant de moduler l’expression génique et contrôler le développement des mammifères. La protéine Mecp2 (Methyl CpG binding protein 2), dont le gène est situé sur le chromosome X, appartient à la famille des protéines de liaison à l’ADN méthylé. Sur la base de sa structure et de ses interactions Mecp2 a été décrit comme un répresseur de l’expression des gènes. A l’heure actuelle, son implication en tant qu’activateur de la transcription et organisateur de la structure chromatinienne lui confère un rôle plus global dans la régulation de l’épigénome. Des mutations de MECP2 conduisent à des troubles neurologiques dont le principal est le syndrome de Rett (RTT). Cette pathologie dominante liée à l’X affecte principalement les jeunes filles (incidence: 1/15000 naissances). Même si les causes précises du phénotype RTT ne sont pas connues, le profil d’expression de Mecp2 est en lien avec la synaptogenèse, la maturation et la maintenance des réseaux neuronaux. A mon arrivée en thèse l’équipe qui m’a accueilli venait d’identifier des déficits neuronaux, affectant notamment les groupes catécholaminergiques bulbaires et périphériques, à l’origine de troubles respiratoires chez un modèle murin de cette pathologie. Mon travail de thèse a permis de caractériser l’évolution postnatale des déficits moteurs et physiologiques affectant la souris Mecp2-déficiente. L’étude de structures catécholaminergiques d’intérêt telles que la Substantia Nigra et le Locus Coeruleus a révélé que les neurones dopaminergiques et noradrénergiques centraux ont un métabolisme affecté. Le nombre de neurones immunomarqués apparait significativement réduit dans ces groupes ce qui résulterait d’une perte progressive du phénotype « catécholaminergique », en l’absence de mort cellulaire. Nos données suggèrent que ces atteintes constituent un corrélat neuropathologique aux troubles comportementaux observés chez les souris Mecp2-déficientes. Ainsi certains troubles moteurs ont pu être améliorés, à l’aide d’un agent pharmacologique pro-dopaminergique, la L-Dopa. En relation avec les déficits en Bdnf (Brain-derived neurotrophic factor) décrits chez les patientes et les souris Mecp2-déficientes, nous avons identifié qu’une modification du dosage de Mecp2 induit une dérégulation de gènes (Htt, Hap1) codant des protéines impliquées dans le transport intracellulaire des vésicules de Bdnf. Nos travaux nous permettent de postuler que chez la souris Mecp2-déficiente, une altération de la dynamique de transport des vésicules chargées en Bdnf pourrait exacerber le déficit d’expression de cette neurotrophine. Notre traitement des souris Mecp2-déficientes par la cystéamine, une molécule capable d’agir sur les contenus, la libération et la sécrétion du Bdnf permet d’augmenter la survie des animaux et de réduire leurs troubles moteurs. Nos résultats montrent que les déficiences en Mecp2 entrainent des déficits de transport axonal du Bdnf qui s’ajoutent aux déficits de production du Bdnf. Par ailleurs, avec l’utilisation d’agents pharmacologiques agissant sur ce transport, nous offrons de nouvelles perspectives thérapeutiques. / DNA methylation is the major modification of eukaryotic genomes and plays an essential role in mammalian development. The protein Mecp2 (Methyl CpG binding protein 2), encoded by a gene located on the X chromosome, belongs to the ‘Methyl Binding domain’ protein family. Based on its structure and its interactions Mecp2 has historically been described as a repressor of expression for many genes. Currently, its involvement as an activator of transcription and its role in chromatin architecture suggests that it could be a global regulator of the epigenome. Mutations in MECP2 lead to neurological disorders, among which Rett syndrome (RTT). This dominant X-linked pathology mainly affects girls (incidence: 1/15000 live births). Although the precise causes of the RTT phenotype are unknown, the pattern of Mecp2 expression is related to synaptogenesis, maturation and neuromaintenance. Before my integration in the ‘Human Neurogenetics’ team, this group identified neural deficits, affecting brainstem and peripheral catecholaminergic cell groups, causing respiratory disturbances in a mouse model of this disease. My thesis work enabled the characterization of the postnatal physiological and motor deficits affecting the Mecp2-deficient mice. The study of catecholaminergic structures of interest such as the substantia nigra pars compacta and the locus coeruleus has revealed that the central noradrenergic and dopaminergic neurons are affected in their metabolism. The number of immunolabelled neurons of these groups appears significantly reduced and would result in a gradual loss of the mature ‘catecholaminergic’ phenotype, in the absence of cell death. Our data suggest that these defects are a neuropathological correlate for behavioral disorders observed in Mecp2-deficient mice. Some motor deficits have been improved, with L-Dopa, a pro-dopaminergic drug. In relation with Bdnf (Brain-derived neurotrophic factor) reduction described in patients and Mecp2-deficient mice, we identified that a change in the dosage of Mecp2 deregulates genes (Htt, Hap1) encoding proteins involved in the intracellular transport of Bdnf. Our work allows to postulate that in the Mecp2-deficient neurons, an altered dynamics of Bdnf vesicles transport could exacerbate the deficit of expression of this neurotrophin. Our treatment of Mecp2-deficient mice with cysteamine, a molecule able to increase Bdnf contents and enhancing its release and secretion, increased the survival of the animals and reduced their motor defects. Our results show that the Mecp2-deficiencies lead to alteration in the axonal transport of Bdnf in addition to deficits in Bdnf production. In addition, by the use of pharmacological agents that affect this transport, we offer new therapeutic perspectives.

Diss. (sammanfattning) Stockholm : Karol. inst., 2005. / Härtill 5 uppsatser.

La maladie d’Alzheimer (MA) se caractérise par une perte mnésique progressive et au plan neuropathologique par le dépôt extracellulaire de plaques amyloïdes, résultant de l’agrégation de peptides amyloïdes (Aβ), et par l’apparition d’une dégénérescence neurofibrillaire (DNF) constituée d’agrégats intraneuronaux de protéines Tau hyper et anormalement phosphorylées. L’évolution des déficits cognitifs des patients est particulièrement corrélée à la progression spatio-temporelle de la DNF. A l’heure actuelle, il n’existe aucun traitement curatif de la maladie. Le cholestérol joue un rôle central dans la physiopathologie de la MA. En particulier, l’allèle ε4 du gène de l’apolipoprotéine E, transporteur cérébral essentiel du cholestérol, est le principal facteur de risque génétique des formes sporadiques de la MA. De nombreuses études in vitro montrent qu’une surcharge en cholestérol induit la production d’Aβ pathogènes et qu’inversement, une déplétion en cholestérol entraîne une diminution de la voie amyloïde. Le cholestérol ne peut pas passer librement la barrière hémato-encéphalique (BHE). Le cholestérol cérébral est exclusivement synthétisé in situ. Le cholestérol cérébral en excès doit être exporté dans la circulation sanguine pour être métabolisé. Pour franchir la BHE, sa conversion en 24(S)-hydroxycholestérol est nécessaire, étape contrôlée par la cholestérol 24-hydroxylase (CYP46A1). Deux précédents travaux de thèse effectués dans le laboratoire ont permis de mettre en évidence des connexions étroites entre le métabolisme du cholestérol et la MA in vivo. La surexpression intracérébrale de CYP46A1 dans un modèle murin amyloïde à l’aide d’un vecteur viral adéno-associé (AAV) a conduit à la diminution de la production d’Aβ, des plaques amyloïdes et à l’amélioration des performances mnésiques des animaux. A l’inverse, l’inhibition de l’expression de CYP46A1 dans l’hippocampe de souris sauvages induit la production d’Aβ, la phosphorylation de Tau et des défauts mnésiques chez la souris. L’objectif de mon travail de doctorat a été de déterminer s’il existait un lien direct entre CYP46A1 et la pathologie Tau et si la modulation du métabolisme du cholestérol pourrait avoir un effet bénéfique sur la pathologie Tau associée à la MA. Pour répondre à ces questions, le modèle murin THY-Tau22, qui développe une pathologie Tau de type Alzheimer, a été utilisé. Cette pathologie, essentiellement hippocampique, est évolutive et associée à des déficits mnésiques. Dans l’hippocampe des souris THY-Tau22, le cholestérol libre total n’est pas modifié, alors que l’expression protéique de CYP46A1 est diminuée, et en conséquence le contenu en 24(S)-hydroxycholestérol. L’expression protéique de CYP46A1 dans l’hippocampe est également réduite dans un autre modèle murin de pathologie Tau, le modèle THY-Tau30. Ainsi, la pathologie Tau semble être à l’origine de la diminution de l’expression protéique de CYP46A1. Afin de déterminer si la surexpression de CYP46A1 chez la souris THY-Tau22 pouvait améliorer son phénotype biochimique, neuropathologique et clinique, un vecteur AAV codant pour CYP46A1 a été injecté dans l’hippocampe de souris THY-Tau22 âgées de trois mois et demi. Deux mois et demi après injection, la surexpression de CYP46A1 chez les souris THY-Tau22 induit une restauration de la concentration hippocampique en 24(S)-hydroxycholestérol et une augmentation de l’expression des gènes impliqués dans la synthèse du cholestérol, et plus particulièrement dans la voie du mévalonate. Deux mois et demi et cinq mois et demi post-injection, la surexpression de CYP46A1 entraîne une restauration complète des performances mnésiques des animaux qui s’accompagne d’un rétablissement de la dépression à long terme, de la longueur des dendrites secondaires, de la densité synaptique et de l’expression des gènes d’activité précoce dans l’hippocampe. (...) / Alzheimer’s disease (AD) is characterized by a progressive memory loss and neuropathologically by senile plaques and neurofibrillary tangles (NFTs). Senile plaques are constituted of extracellular amyloid peptide (Aβ) deposits while NFTs result from the accumulation and the aggregation of intracellular hyperphosphorylated Tau proteins. Spatiotemporal progression of NFTs particularly correlates with cognitive impairments. To date, there is no curative treatment for this disease. Cholesterol plays a central role in AD physiopathology. Indeed, the ε4 allele of the apolipoprotein E, the brain’s principal cholesterol-carrier protein, is the main genetic risk factor for sporadic forms of AD. Numerous in vitro studies have shown that cholesterol overload induces production of pathogenic Aβ and conversely, cholesterol depletion causes a reduction of the amyloidogenic pathway. In adult, brain cholesterol is exclusively synthesized in situ. Brain cholesterol is not able to freely cross the blood brain barrier and its major exportable form is 24(S)-hydroxycholesterol generated by the cholesterol 24-hydroxylase (CYP46A1). Two previous thesis works in this laboratory highlighted narrow connections between cholesterol metabolism and AD in vivo. The intracerebral overexpression of CYP46A1 mediated by an adeno-associated viral (AAV) vector, in a murine amyloid model, led to the decrease of Aβ production, senile plaques and improvement of memory abilities. At the opposite, hippocampal CYP46A1 inhibition in wild-type (WT) mice induced Aβ production, Tau phosphorylation and memory impairments. The aim of this thesis work was to determine whether there was a direct link between CYP46A1 and Tau pathology and whether cholesterol metabolism modulation could have a beneficial effect on AD-like Tau pathology. In order to answer these questions, the THY-Tau22 mouse model, that develops AD-like Tau pathology, was used. In this model, the pathology mainly occurs in the hippocampus, it is progressive, and associated with memory deficits. In THY-Tau22 mice, total free cholesterol in the hippocampus was unchanged, whereas both CYP46A1 protein expression and 24(S)-hydroxycholesterol content were decreased. Furthermore, we also demonstrated that CYP46A1 protein expression was reduced in another murine model of Tau pathology, the THY-Tau30 model. Therefore, it may suggest that Tau pathology can be responsible for CYP46A1 decrease. We next determined whether CYP46A1 overexpression in the THY-Tau22 mouse could improve its biochemical, clinical and neuropathologic phenotype. For this purpose, an AAV vector encoding CYP46A1 was injected in the hippocampus of 3.5-month-old WT and THY-Tau22 mice. Two and a half months after injection, hippocampal CYP46A1 overexpression in THY-Tau22 mice induced restoration of hippocampal 24(S)-hydroxycholesterol content and increased expression of genes involved in cholesterol synthesis, more particularly in the mevalonate pathway. Two and a half and five and a half months post-injection, CYP46A1 overexpression resulted in a complete restoration of memory abilities and was accompanied by restoration of long-term depression, length of secondary dendrites, synaptic density and expression of immediate-early genes in hippocampus. Despite this, abnormal Tau hyperphosphorylation and gliosis, that characterizes this model, remained unchanged after CYP46A1 overexpression. Altogether, these results suggest a direct connection between Tau pathology and CYP46A1 in vivo. In other words, Tau pathology could lead to memory deficits via CYP46A1 decrease. These data, together with the fact that CYP46A1 overexpression can modulate the amyloid pathology in mice, suggest that CYP46A1 may be a relevant therapeutic target for AD.

Das Ziel der Arbeit war es, mittels biochemischer und molekulargenetischer Untersuchungen die Rolle des partiellen 21-Hydroxylase-Mangels in der Pathogenese des Polyzystischen Ovar Syndroms (PCOS) und des Ovariellen Überstimulationssyndroms (OHSS) zu beleuchten sowie ein charakteristisches biochemisches Profil für Patientinnen mit erhöhtem Risiko zur Ausbildung eines OHSS aufzudecken. In die Studie wurden 62 Patientinnen eingeschlossen, 23 Kontrollpersonen und 39 PCOS-Patientinnen, von denen 17 Patientinnen anamnestisch mindestens eine Episode eines OHSS aufwiesen. Umfangreiche biochemische Analysen dienten zur Bestimmung der partiellen 21-Hydroxylase-Insuffizienz, zur Untersuchung des Ursprungs des Androgenüberschusses (ACTH und LHRH-Test) und zur Charakterisierung des metabolischen Profils (Leptin, Insulin, SHBG, IGF-1). Zur Darstellung des Gentotyps führten wir die lückenlose Untersuchung des CYP21A2-Gens auf Mutationen und Polymorphismen durch. Die androgenen Steroide wiesen ein bei den PCOS-Patientinnen im Vergleich zu den Kontrollpatientinnen erhöhtes Niveau auf, ohne dass sich ein klare Unterscheidung zwischen adrenalem und ovariellem Ursprung abzeichnete. Bei den OHSS-Patientinnen dominierten die ovariellen Androgene. Die Leptinwerte waren in der PCOS-Gruppe erhöht, besonders bei den Patientinnen mit OHSS. Die Frequenz heterozygoter Punktmutationen lag in unserer PCOS-Gruppe mit 23% deutlich höher als in der Kontrollgruppe mit 8%. Es ergab sich kein signifikanter Unterschied zwischen PCOS-Patientinnen mit und ohne OHSS. Die Allelfrequenz der detektierten Polymorphismen unterschied sich nicht zwischen PCOS-Patientinnen und Kontrollen. Von insgesamt 17 Patientinnen mit biochemischen Auffälligkeiten waren 8 Trägerinnen einer heterozygoten Mutation. Im Gegensatz dazu wiesen nur 8 der 11 Patientinnen mit Punktmutation biochemische Abweichungen auf. Es ergab sich also nicht für jeden Fall eine eindeutige Genotyp-Phänotyp-Korrelation. / This study was designed to evaluate the possible role of partial 21-Hydroxylase Deficiency in the pathogenesis of the Polycystic Ovary Syndrome (PCOS) and the Ovarian Hyperstimulation Syndrome (OHSS) by means of biochemical and molecular genetic investigations, as well as to identify the biochemical profile typical of patients with an elevated risk of developing an OHSS. 62 female patients were included in the study, 23 controls and 39 PCOS patients. 17 of these had at least one anamnestic episode of OHSS. Extensive biochemical investigations were used to determine partial 21-OHase Deficiency as well as the source of the androgen excess (ACTH and LHRH tests) and to describe the metabolic profile (leptin, insulin, SHBG and IGF-1). For genotypic characterization, we screened the CYP21A2 gene for any mutation or polymorphism. Androgens were elevated in the PCOS group without a clear differentiation into adrenal or ovarian origin. Amongst patients with OHSS, the ovarian androgens were dominant. Higher leptin levels were measured in the PCOS group, especially in patients with OHSS. The frequency of heterozygous point mutations was 23% in our PCOS group, compared to 8% amongst control patients. There was no relevant difference between PCOS patients with or without an OHSS. The frequency of polymorphisms did not differ between the groups. We found relevant heterozygous point mutations in 8 of the 17 patients with biochemical deviations. In contrast to this only 8 of the 11 patients with point mutations showed biochemical derangements indicating no clear Genotype-Phenotyp-correlation.